GSK701

Product vision
  • Uncomplicated malaria treatment and resistance management (TPP-1)
MoA
  • Inhibition of Plasmodium falciparum ACS10/11
Key features
  • Novel mode of action and structure
  • Highly potent and active against resistant strains
  • Fast killing in vitro and in vivo
  • Low single dose prediction
Challenges
  • Low potency on P. vivax and P. knowlesi malaria
  • Limited solubility of crystalline material
Status
  • Preclinical development
Next milestone
  • Initiate first-in-human study
Previously
  • Discovery by GSK with support from the Wellcome Trust
  • Full reference name is MMV1582367
MMV Project Director
  • Dr BenoĆ®t Bestgen